0 Items - $0.00
A to Z

Alternative structural projections:


8- Bromo- 2'- O- methyladenosine- 3', 5'- cyclic monophosphate ( 8-Br-2'-O-Me-cAMP ), sodium salt
Epac agonist
Cat. No.: B 022
CAS No.: [612513-13-0]
Shipping: ambient
Product Name Price (net) Qty
Cat. No.: B 022-05
Unit: 5 µmol / ~2.2 mg
For other salt forms please inquire. Specific activator of the exchange protein activated by cyclic AMP (Epac) or cAMP-GEF, respectively, while protein kinase A is not affected. Suitable for direct comparison with common 8-Br-cAMP (Cat. No. B 007), which activates both, PKA and Epac. Detailed technical information and updated reference list available. References: Christensen et al., J. Biol. Chem., 278, 35394 - 35402 (2003); Traver et al., Mol. Pharmacol., 70, 30 - 40 (2006).
Cat. No. B 022
CAS number [612513-13-0]
Purity > 98% HPLC
Salt form Sodium
Storage temperature -20°C / -4°F
Molecular formula C₁₁H₁₂BrN₅O₆P · Na
Molecular weight [g/mol] 444.1
Modifications 8-cAMP, 2'-cAMP
Target Epac Activator
Lipophilicity 1.69
Absorption max [nm] 264
Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹] 17000
  • 1. Schwede F., Bertinetti D., Langerijs C. N., Hadders M. A., Wienk H., Ellenbroek J. H., de Koning E. J. P., Bos J. L., Herberg F. W., Genieser H.-G., Janssen R. A.Rehmann H., PLoS Biol., 13, 1 - 26 (2015), "Structure-Guided Design of Selective Epac1 and Epac2 Agonists"
  • 2. Börner S., Schwede F., Schlipp A., Berisha F., Calebiro D., Lohse M. J.Nikolaev V. O., Nat. Protoc., 6, 427 - 438 (2011), "FRET Measurements of Intracellular cAMP Concentrations and cAMP Analog Permeability in Intact Cells"
  • 3. Voisin P.Bernard M., J. Neurochem., 110, 318 - 327 (2009), "Cyclic AMP-dependent Activation of Rhodopsin Gene Transcription in Cultured Retinal Precursor Cells of Chicken Embryo"
  • 4. Li J., O'Connor K. L., Cheng X., Mei F. C., Uchida T., Townsend C. M.Evers B. M., Mol. Endocrinol., 21, 159 - 171 (2007), "Cyclic AMP-stimulated Neurotensin Secretion is Mediated Through Rap1 Downstream of Both Epac and PKA Signaling Pathways"
  • 5. Kooijman R., Gerlo S.Verdood P., Patent WO 2007/006544, 0, 0 - 0 (2007), "Cyclic Adenosine Monophosphate Compounds for the Treatment of Immune-Related Disorders"
  • 6. Traver S., Marien M., Martin E., Hirsch E. C.Michel P. P., Mol. Pharmacol., 70, 30 - 40 (2006), "The Phenotypic Differentiationof Locus Coeruleus Noradrenergic Neurons Mediated by BDNF is Enhanced by Corticotropin Releasing Factor Through the Activation of a cAMP-dependent Signaling Pathway"
  • 7. Dao K. K., Teigen K., Kopperud R. K., Hodneland E., Schwede F., Christensen A. E., Martinez A.Doeskeland S. O., J. Biol. Chem., 281, 21500 - 21511 (2006), "Epac1 and cAMP-dependent Protein Kinase Holoenzyme Have Similar cAMP Affinity, but Their cAMP Domains Have Distinct Structural Features and Cyclic Nucleotide Recognition"
  • 8. Genieser H.-G., Bos J. L., Christensen A. E., Doeskeland S. O., Havemann U., Manzau U., Rehmann H.Schwede F., Poster #THP016 Montreal, 12, 0 - 0 (2004), "Analogues of Cyclic AMP to Distinguish Between PKA and Epac"
  • 9. Christensen A. E., Selheim F., de Rooij J., Dremier S., Schwede F., Dao K. K., Martinez A., Maenhaut C., Bos J. L., Genieser H.-G.Doeskeland S. O., J. Biol. Chem., 278, 35394 - 35402 (2003), "cAMP Analog Mapping of Epac1 and cAMP-Kinase. Discriminating Analogs Demonstrate that Epac and cAMP-Kinase Act Synergistically to Promote PC-12 Cell Neurite Extension"